FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W45024897> ?p ?o ?g. }

• W45024897 abstract "OBJECTIVE: This was an open prospective study to determined clinical response to albuterol in Dok-7 CMS. BACKGROUND: Congenital myasthenic syndromes (CMS) are heterogeneous genetic diseases which can have different management in specific subgroups. In CMS related to Dok-7 deficiency (Dok-7 CMS), treatment can be accomplished with cholinesterase inhibitors, or according to the response, associate at 3-4 DAP. The ephedrine can be used in the treatment of Dok-7 CMS, but it cannot be prescribed in USA. Albuterol, or salbutamol, is a selective B2-adrenergic agonist, which was previous described associated with improvement of Dok-7 CMS. However, more prospective studies are necessary to determinate the most effective dosing regimen and long-term response. DESIGN/METHODS: Albuterol was prescribed at dose of 2 mg three times daily (6mg/day) for all patients. The response was assessment by QMG score at baseline, 3, 6, 9 and 12 months; ADL-MG score and 6 minutes walking test at baseline and after 12 months in follow-up clinic visits. Tolerance to albuterol was evaluated. RESULTS: The sample population consisted of 5 patients (2 male and 3 female), with a mean age of 27 + 11.06 years, who presented CMS with c.1124_1127dupTGCC and/or p.S45L mutations in DOK7 gene. We noted a progressive response to treatment in QMG score since 3 months of albuterol treatment. In ADL-MG scores and 6 minutes walking test, comparison between baseline and after 12 months reveals an important beneficial response to albuterol treatment. The side effects of albuterol were well tolerated in all patients. CONCLUSIONS: Albuterol was an effective treatment to Dok-7 CMS. This study provides class IV evidence that albuterol given at dose 6 mg/day improves measured by the QMG score, ADL-MG score and 6 minutes walking test. The dose of albuterol was well-tolerated and lesser than previous described to treat patients with Dok-7 CMS. Disclosure: Dr. Lorenzoni has nothing to disclose. Dr. Scola has received personal compensation for activities with Merck Serono as scientific advisor board. Dr. Kay has nothing to disclose. Dr. Paranhos has nothing to disclose. Dr. Pinheiro has nothing to disclose. Dr. Filla has nothing to disclose. Dr. Lochmuller has nothing to disclose. Dr. Werneck has nothing to disclose." @default.
• W45024897 created "2016-06-24" @default.
• W45024897 creator A5004690210 @default.
• W45024897 creator A5015800703 @default.
• W45024897 creator A5016560014 @default.
• W45024897 creator A5020789258 @default.
• W45024897 creator A5062908694 @default.
• W45024897 creator A5069614405 @default.
• W45024897 creator A5085333671 @default.
• W45024897 creator A5087334418 @default.
• W45024897 date "2013-02-12" @default.
• W45024897 modified "2023-10-17" @default.
• W45024897 title "Albuterol Treatment in Congenital Myastenic Syndrome with Dok-7 Mutation: An Open Prospective Study (IN1-1.002)" @default.
• W45024897 hasPublicationYear "2013" @default.
• W45024897 type Work @default.
• W45024897 sameAs 45024897 @default.
• W45024897 citedByCount "0" @default.
• W45024897 crossrefType "journal-article" @default.
• W45024897 hasAuthorship W45024897A5004690210 @default.
• W45024897 hasAuthorship W45024897A5015800703 @default.
• W45024897 hasAuthorship W45024897A5016560014 @default.
• W45024897 hasAuthorship W45024897A5020789258 @default.
• W45024897 hasAuthorship W45024897A5062908694 @default.
• W45024897 hasAuthorship W45024897A5069614405 @default.
• W45024897 hasAuthorship W45024897A5085333671 @default.
• W45024897 hasAuthorship W45024897A5087334418 @default.
• W45024897 hasConcept C126322002 @default.
• W45024897 hasConcept C170493617 @default.
• W45024897 hasConcept C188816634 @default.
• W45024897 hasConcept C2776042228 @default.
• W45024897 hasConcept C2777210258 @default.
• W45024897 hasConcept C2777394947 @default.
• W45024897 hasConcept C2781413609 @default.
• W45024897 hasConcept C42219234 @default.
• W45024897 hasConcept C71924100 @default.
• W45024897 hasConcept C80161118 @default.
• W45024897 hasConceptScore W45024897C126322002 @default.
• W45024897 hasConceptScore W45024897C170493617 @default.
• W45024897 hasConceptScore W45024897C188816634 @default.
• W45024897 hasConceptScore W45024897C2776042228 @default.
• W45024897 hasConceptScore W45024897C2777210258 @default.
• W45024897 hasConceptScore W45024897C2777394947 @default.
• W45024897 hasConceptScore W45024897C2781413609 @default.
• W45024897 hasConceptScore W45024897C42219234 @default.
• W45024897 hasConceptScore W45024897C71924100 @default.
• W45024897 hasConceptScore W45024897C80161118 @default.
• W45024897 hasOpenAccess W45024897 @default.
• W45024897 hasRelatedWork W1555961812 @default.
• W45024897 hasRelatedWork W1595532489 @default.
• W45024897 hasRelatedWork W1601269276 @default.
• W45024897 hasRelatedWork W1828324206 @default.
• W45024897 hasRelatedWork W2261758718 @default.
• W45024897 hasRelatedWork W2473765924 @default.
• W45024897 hasRelatedWork W2543494082 @default.
• W45024897 hasRelatedWork W2550916925 @default.
• W45024897 hasRelatedWork W2608552207 @default.
• W45024897 hasRelatedWork W2725021787 @default.
• W45024897 hasRelatedWork W2752398826 @default.
• W45024897 hasRelatedWork W2805067797 @default.
• W45024897 hasRelatedWork W2916438206 @default.
• W45024897 hasRelatedWork W3006118591 @default.
• W45024897 hasRelatedWork W3092253534 @default.
• W45024897 hasRelatedWork W3110928294 @default.
• W45024897 hasRelatedWork W55236766 @default.
• W45024897 hasRelatedWork W59636586 @default.
• W45024897 hasRelatedWork W2132749419 @default.
• W45024897 hasRelatedWork W2716721197 @default.
• W45024897 hasVolume "80" @default.
• W45024897 isParatext "false" @default.
• W45024897 isRetracted "false" @default.
• W45024897 magId "45024897" @default.
• W45024897 workType "article" @default.